Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Armandi

Showing results (11-20 of 122) with videos related to

Pageof 13
Sort By:
Alimentary Pharmacology & Therapeutics|May 6, 2024
Editorial: Can dietary gluten restriction improve hepatic steatosis? Authors' replyAngelo Armandi, Detlef Schuppan, Jörn M Schattenberg
Alimentary Pharmacology & Therapeutics|June 11, 2024
Letter: Breaking new ground-Understanding the role of ATI-free diet in managing MASLD-Authors' replyAngelo Armandi, Detlef Schuppan, Jörn M Schattenberg
Clinics in Liver Disease|May 16, 2026
Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated SteatohepatitisAngelo Armandi, Elisabetta Bugianesi, Rohit Loomba, et al.
Metabolites|April 3, 2021
Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver DiseaseAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2021
Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosisJesús Rivera-Esteban, Angelo Armandi, Salvador Augustin, et al.
Minerva Gastroenterology|June 3, 2021
Role of triglycerides to high-density lipoprotein cholesterol ratio in non-alcoholic fatty liver disease progressionChiara Rosso, Angelo Armandi, Aurora Nicolosi, et al.
Metabolism: Clinical and Experimental|November 21, 2024
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillanceAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Panminerva Medica|October 19, 2020
Moving towards core antigen for the management of patients with overt and occult HBV infectionAngelo Armandi, Chiara Rosso, Davide G Ribaldone, et al.
Nature Reviews. Gastroenterology & Hepatology|February 17, 2025
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Clinics and Research in Hepatology and Gastroenterology|January 14, 2021
Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?Chiara Rosso, Gian Paolo Caviglia, Angelo Armandi, et al.
Pageof 13

Showing results (11-20 of 122) with videos related to

Sort By:
Pageof 13
Alimentary Pharmacology & Therapeutics|May 6, 2024
Editorial: Can dietary gluten restriction improve hepatic steatosis? Authors' replyAngelo Armandi, Detlef Schuppan, Jörn M Schattenberg
Alimentary Pharmacology & Therapeutics|June 11, 2024
Letter: Breaking new ground-Understanding the role of ATI-free diet in managing MASLD-Authors' replyAngelo Armandi, Detlef Schuppan, Jörn M Schattenberg
Clinics in Liver Disease|May 16, 2026
Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated SteatohepatitisAngelo Armandi, Elisabetta Bugianesi, Rohit Loomba, et al.
Metabolites|April 3, 2021
Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver DiseaseAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2021
Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosisJesús Rivera-Esteban, Angelo Armandi, Salvador Augustin, et al.
Minerva Gastroenterology|June 3, 2021
Role of triglycerides to high-density lipoprotein cholesterol ratio in non-alcoholic fatty liver disease progressionChiara Rosso, Angelo Armandi, Aurora Nicolosi, et al.
Metabolism: Clinical and Experimental|November 21, 2024
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillanceAngelo Armandi, Chiara Rosso, Gian Paolo Caviglia, et al.
Panminerva Medica|October 19, 2020
Moving towards core antigen for the management of patients with overt and occult HBV infectionAngelo Armandi, Chiara Rosso, Davide G Ribaldone, et al.
Nature Reviews. Gastroenterology & Hepatology|February 17, 2025
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatmentChristopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Clinics and Research in Hepatology and Gastroenterology|January 14, 2021
Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?Chiara Rosso, Gian Paolo Caviglia, Angelo Armandi, et al.
Pageof 13